- Education, Training & Outreach
- Patients & Caregivers
- For Investigators
- News on Dementia
- Media Room
- Donate & Contact
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease
What is the purpose of this study?
The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BMS241027, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called tau, in the fluid surrounding the brain. We hope that BMS241027 can decrease the levels of tau.
Who is eligible?
We are looking for participants who:
-- have been diagnosed with mild Alzheimer's disease
-- are between the age of 50 and 90
-- have a reliable caregiver or family member who is able to accompany them to study visits
-- are in stable medical condition
-- are willing to undergo MRI and lumbar punctures
People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study.
Please see the attached study description for more information.
|BMS web blurb.doc||37 KB|